NASDAQ:PZRX - PhaseRx Stock Price, Price Target & More

$0.2806 -0.03 (-9.66 %)
(As of 04/23/2018 04:59 AM ET)
Previous Close$0.2806
Today's Range$0.2750 - $0.34
52-Week Range$0.22 - $1.95
Volume1.05 million shs
Average Volume1.24 million shs
Market Capitalization$268,881.00
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About PhaseRx (NASDAQ:PZRX)

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The Company's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.

Receive PZRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PZRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:PZRX
CUSIPN/A
Phone+1-206-8056300

Debt

Debt-to-Equity Ratio-12.03%
Current Ratio2.14%
Quick Ratio2.14%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$370,000.00
Price / Sales8.87
Cash FlowN/A
Price / CashN/A
Book Value$0.79 per share
Price / Book0.36

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-20,130,000.00
Net MarginsN/A
Return on Equity-332.32%
Return on Assets-124.69%

Miscellaneous

Employees21
Outstanding Shares11,690,000

How to Become a New Pot Stock Millionaire

PhaseRx (NASDAQ:PZRX) Frequently Asked Questions

What is PhaseRx's stock symbol?

PhaseRx trades on the NASDAQ under the ticker symbol "PZRX."

How were PhaseRx's earnings last quarter?

PhaseRx Inc (NASDAQ:PZRX) announced its earnings results on Thursday, November, 9th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.14. View PhaseRx's Earnings History.

Who are some of PhaseRx's key competitors?

Who are PhaseRx's key executives?

PhaseRx's management team includes the folowing people:
  • Steven H. Gillis Ph.D., Independent Chairman of the Board (Age 63)
  • Robert W. Overell Ph.D., President, Chief Executive Officer, Principal Accounting Officer, Secretary, Director (Age 61)
  • Sean Monahan Ph.D., Vice President - Chemistry
  • Mary G. Prieve Ph.D., Vice President - Biology
  • Gordon Brandt M.D., Chief Medical Officer (Age 57)
  • James D. Watson, Head of Corporate Development
  • Paul H. Johnson Ph.D., Director (Age 73)
  • Brian G. Atwood, Independent Director (Age 64)
  • Michelle Renee Griffin, Independent Director (Age 51)
  • Peggy V. Phillips, Independent Director (Age 63)

When did PhaseRx IPO?

(PZRX) raised $18 million in an initial public offering (IPO) on Wednesday, May 18th 2016. The company issued 3,700,000 shares at a price of $5.00 per share. Laidlaw & Company (UK) Ltd. and Roth Capital Partners served as the underwriters for the IPO.

Has PhaseRx been receiving favorable news coverage?

Press coverage about PZRX stock has been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. PhaseRx earned a daily sentiment score of 0.04 on Accern's scale. They also assigned media headlines about the company an impact score of 44.21 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of PhaseRx?

Shares of PZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PhaseRx's stock price today?

One share of PZRX stock can currently be purchased for approximately $0.2806.

How big of a company is PhaseRx?

PhaseRx has a market capitalization of $268,881.00 and generates $370,000.00 in revenue each year. PhaseRx employs 21 workers across the globe.

How can I contact PhaseRx?

PhaseRx's mailing address is 410 W Harrison St Ste 300, SEATTLE, WA 98119-4034, United States. The company can be reached via phone at +1-206-8056300 or via email at [email protected]


MarketBeat Community Rating for PhaseRx (PZRX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  90
MarketBeat's community ratings are surveys of what our community members think about PhaseRx and other stocks. Vote "Outperform" if you believe PZRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PZRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

PhaseRx (NASDAQ:PZRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for PhaseRx in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

PhaseRx (NASDAQ:PZRX) Consensus Price Target History

Price Target History for PhaseRx (NASDAQ:PZRX)

PhaseRx (NASDAQ:PZRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017LaidlawDowngradeBuy -> NeutralN/AView Rating Details
6/17/2016Roth CapitalInitiated CoverageBuy$8.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

PhaseRx (NASDAQ:PZRX) Earnings History and Estimates Chart

Earnings by Quarter for PhaseRx (NASDAQ:PZRX)

PhaseRx (NASDAQ PZRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.37)($0.23)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.21)($0.30)ViewN/AView Earnings Details
5/12/2017Q1 2017($0.29)($0.35)ViewN/AView Earnings Details
3/27/2017Q4 2016($0.37)($0.30)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.28)($0.29)ViewN/AView Earnings Details
8/2/2016Q2 2016($0.23)($0.59)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

PhaseRx (NASDAQ:PZRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

PhaseRx (NASDAQ PZRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 44.69%
Institutional Ownership Percentage: 2.47%
Insider Trading History for PhaseRx (NASDAQ:PZRX)

PhaseRx (NASDAQ PZRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2016Richard J UlevitchDirectorSell455,777$0.01$4,557.77View SEC Filing  
5/23/2016Venture Fund Vii Lp ArchMajor ShareholderBuy1,000,000$5.00$5,000,000.0010,048View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

PhaseRx (NASDAQ PZRX) News Headlines

Source:
DateHeadline
PhaseRx (PZRX) Set to Announce Earnings on MondayPhaseRx (PZRX) Set to Announce Earnings on Monday
www.americanbankingnews.com - March 19 at 1:28 AM
PhaseRx (PZRX) Upgraded at ValuEnginePhaseRx (PZRX) Upgraded at ValuEngine
www.americanbankingnews.com - February 4 at 3:56 PM
BRIEF-Phaserx, Roivant Enter Into Asset Purchase AgreementBRIEF-Phaserx, Roivant Enter Into Asset Purchase Agreement
www.reuters.com - February 2 at 4:34 PM
[$$] Roivant Sciences to Buy PhaseRx[$$] Roivant Sciences to Buy PhaseRx
finance.yahoo.com - February 1 at 4:24 PM
BRIEF-Phaserx Revokes Proposed Distribution Record DateBRIEF-Phaserx Revokes Proposed Distribution Record Date
www.reuters.com - January 19 at 4:33 PM
[$$] Firm Retention Summary: PhaseRx Inc.[$$] Firm Retention Summary: PhaseRx Inc.
finance.yahoo.com - December 26 at 11:36 PM
PhaseRx Receives Decision from the Nasdaq Hearings Panel for Continued Listing of SharesPhaseRx Receives Decision from the Nasdaq Hearings Panel for Continued Listing of Shares
finance.yahoo.com - December 13 at 11:06 AM
PhaseRx files for Chapter 11 bankruptcy protectionPhaseRx files for Chapter 11 bankruptcy protection
www.marketwatch.com - December 12 at 11:14 AM
[$$] PhaseRx, a Developer of Liver Drugs, Files for Bankruptcy[$$] PhaseRx, a Developer of Liver Drugs, Files for Bankruptcy
finance.yahoo.com - December 11 at 4:21 PM
PhaseRx Inc (PZRX) Investors Run for the Hills Following Bankruptcy NewsPhaseRx Inc (PZRX) Investors Run for the Hills Following Bankruptcy News
finance.yahoo.com - December 11 at 4:21 PM
PhaseRx Commences Voluntary Chapter 11 Bankruptcy Protection ProceedingPhaseRx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding
finance.yahoo.com - December 11 at 11:25 AM
Biotech Stocks Research Reports Released on PhaseRx, Abeona Therapeutics, Imprimis Pharma, and Jaguar HealthBiotech Stocks' Research Reports Released on PhaseRx, Abeona Therapeutics, Imprimis Pharma, and Jaguar Health
www.bizjournals.com - December 8 at 10:52 AM
PhaseRx (PZRX) Reports Positive Opinion for Orphan Drug Designation for PRX-ASL from EMAPhaseRx (PZRX) Reports Positive Opinion for Orphan Drug Designation for PRX-ASL from EMA
www.streetinsider.com - November 30 at 11:23 AM
PhaseRx Inc (PZRX) Stock Rallies on Investor Optimism Over Orphan Drug Designation in the European UnionPhaseRx Inc (PZRX) Stock Rallies on Investor Optimism Over Orphan Drug Designation in the European Union
finance.yahoo.com - November 28 at 4:10 PM
PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines AgencyPhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency
finance.yahoo.com - November 28 at 10:41 AM
PhaseRx, Inc. (PZRX) Issues  Earnings Results, Beats Estimates By $0.14 EPSPhaseRx, Inc. (PZRX) Issues Earnings Results, Beats Estimates By $0.14 EPS
www.americanbankingnews.com - November 10 at 7:54 PM
PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate UpdatePhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 12:03 PM
Does PhaseRx Inc’s (PZRX) Debt Level Pose A Serious Problem?Does PhaseRx Inc’s (PZRX) Debt Level Pose A Serious Problem?
finance.yahoo.com - November 4 at 9:52 AM
PhaseRx to Present at 5th International mRNA ConferencePhaseRx to Present at 5th International mRNA Conference
finance.yahoo.com - October 31 at 8:22 AM
PhaseRx, Inc. (PZRX) Scheduled to Post Quarterly Earnings on MondayPhaseRx, Inc. (PZRX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:54 AM
PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing OptionsPhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options
finance.yahoo.com - October 27 at 12:34 PM
Featured Company News - PhaseRx Announces Cutback in Workforce; Considers Corporate RestructuringFeatured Company News - PhaseRx Announces Cutback in Workforce; Considers Corporate Restructuring
finance.yahoo.com - October 17 at 4:22 PM
PhaseRx (PZRX) Reports Restructuring, to Review Strategic AlternativesPhaseRx (PZRX) Reports Restructuring, to Review Strategic Alternatives
www.streetinsider.com - October 15 at 6:19 AM
PhaseRx to cut half its workforce, looks into potential mergerPhaseRx to cut half its workforce, looks into potential merger
www.marketwatch.com - October 14 at 7:07 AM
Laidlaw Lowers PhaseRx, Inc. (PZRX) to NeutralLaidlaw Lowers PhaseRx, Inc. (PZRX) to Neutral
www.americanbankingnews.com - October 13 at 4:34 PM
PhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase DeficiencyPhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase Deficiency
finance.yahoo.com - September 22 at 2:59 PM
PhaseRx, Inc. (PZRX) Issues  Earnings Results, Misses Estimates By $0.09 EPSPhaseRx, Inc. (PZRX) Issues Earnings Results, Misses Estimates By $0.09 EPS
www.americanbankingnews.com - August 11 at 7:54 PM
PhaseRx Reports Second Quarter 2017 Financial Results and Provides Corporate UpdatePhaseRx Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 11 at 7:52 AM
Gainers & Losers Of Apr.24: PZRX, BCR, IMNP, ACHN, AKTX...Gainers & Losers Of Apr.24: PZRX, BCR, IMNP, ACHN, AKTX...
www.finanznachrichten.de - April 26 at 5:54 PM
PhaseRx (PZRX) Granted Orphan Drug Designation for PRX-OTC in EuropePhaseRx (PZRX) Granted Orphan Drug Designation for PRX-OTC in Europe
www.streetinsider.com - April 26 at 5:54 PM
PHASERX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsPHASERX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 8 at 4:12 PM
PHASERX, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Shareholder DirectPHASERX, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Shareholder Direct
biz.yahoo.com - March 6 at 6:46 PM
8:30 am PhaseRx confirms orphan drug designation from FDA for PRX-OTC for the treatment of ornithine transcarbamylase deficiency8:30 am PhaseRx confirms orphan drug designation from FDA for PRX-OTC for the treatment of ornithine transcarbamylase deficiency
us.rd.yahoo.com - November 30 at 12:25 PM
PhaseRx clears hurdle to market with FDA rare disease designationPhaseRx clears hurdle to market with FDA rare disease designation
www.bizjournals.com - November 29 at 1:56 PM
PhaseRx (PZRX) Receives Orphan Drug Designation for Treatment of Ornithine Transcarbamylase DeficiencyPhaseRx (PZRX) Receives Orphan Drug Designation for Treatment of Ornithine Transcarbamylase Deficiency
www.streetinsider.com - November 29 at 1:56 PM
PhaseRx Inc. (PZRX) Leaped To Almost A 2-Month High On FDA NewsPhaseRx Inc. (PZRX) Leaped To Almost A 2-Month High On FDA News
www.rttnews.com - November 29 at 1:56 PM
PHASERX, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsPHASERX, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - November 29 at 1:56 PM
PhaseRx (PZRX) Reports Positive Results from Single Escalating Dose Response Study in non-Human PrimatesPhaseRx (PZRX) Reports Positive Results from Single Escalating Dose Response Study in non-Human Primates
www.streetinsider.com - November 10 at 6:55 PM
PHASERX, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and ExhibitsPHASERX, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
biz.yahoo.com - November 8 at 10:34 AM
PHASERX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsPHASERX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - November 7 at 10:54 AM

SEC Filings

PhaseRx (NASDAQ:PZRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

PhaseRx (NASDAQ:PZRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

PhaseRx (NASDAQ PZRX) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.